Dexcom Inc (DXCM)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
- Symbol
- DXCM
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $32.21B
- 52 week range
- 54.11 - 92.59
Valuation
- Share price
- $85.36 (close of 2026-10-02)
- P/E (TTM)
- 33.09x
- Price to book
- 12.29x
- Price to free cash flow
- 22.93x
- Enterprise value
- $32.51B
- Book value per share
- $6.95
Price performance
| Period | Change |
|---|---|
| 1 day | -1.01% |
| 5 days | -1.45% |
| 1 month | -4.83% |
| 3 months | +19.80% |
| 6 months | +37.19% |
| Year to date | +28.61% |
| 1 year | +28.48% |
| 3 years | -9.72% |
| 5 years | -37.91% |
| 10 years | +289.42% |
| All time | +2813.31% |
Members of Congress who disclosed DXCM trades
Jefferson Shreve · Robert Bresnahan · Tina Smith · John Boozman · Kevin Hern
Super investors holding DXCM
Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- 30.46%
- Return on invested capital
- 20.50%
- Return on assets
- 13.19%
- Return on capital employed
- 21.72%
- Gross margin
- 60.10%
- Net margin
- 17.94%
- EBITDA margin
- 24.96%
- Revenue growth
- 15.60%
- Net income growth
- 45.14%
- Free cash flow growth
- 70.79%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 4.36%
- Current ratio
- 1.73x
- Net debt to EBITDA
- 0.19x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $4.66B
- Cost of revenue
- $1.86B
- Gross profit
- $2.80B
- EBITDA
- $1.16B
- Net income
- $836.30M
- Earnings per share
- $2.14
- Research and development
- $599.10M
- Shares outstanding
- 390.20M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $4.66B | $2.80B | $836.30M | $2.14 |
| 2024-12-31 | $4.03B | $2.44B | $576.20M | $1.46 |
| 2023-12-31 | $3.62B | $2.29B | $541.50M | $1.40 |
| 2022-12-31 | $2.91B | $1.88B | $341.20M | $0.88 |
| 2021-12-31 | $2.45B | $1.68B | $216.90M | $0.56 |
| 2020-12-31 | $1.93B | $1.28B | $549.70M | $1.46 |
| 2019-12-31 | $1.48B | $931.50M | $101.10M | $0.28 |
| 2018-12-31 | $1.03B | $663.90M | -$127.10M | $-0.36 |
| 2017-12-31 | $718.50M | $492.10M | -$50.20M | $-0.14 |
| 2016-12-31 | $573.30M | $378.40M | -$65.60M | $-0.20 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 60.10% | 17.94% | 30.46% | 20.50% |
| 2024-12-31 | 60.46% | 14.29% | 27.40% | 11.44% |
| 2023-12-31 | 63.19% | 14.95% | 26.18% | 10.47% |
| 2022-12-31 | 64.72% | 11.73% | 16.01% | 9.40% |
| 2021-12-31 | 68.63% | 8.86% | 10.62% | 19.33% |
| 2020-12-31 | 66.44% | 28.53% | 30.10% | 25.17% |
| 2019-12-31 | 63.11% | 6.85% | 11.45% | 25.90% |
| 2018-12-31 | 64.36% | -12.32% | -19.16% | - |
| 2017-12-31 | 68.49% | -6.99% | -11.97% | - |
| 2016-12-31 | 66.00% | -11.44% | -23.11% | -39.91% |
Cash and debt by year
| Period end | Cash |
|---|---|
| 2025-12-31 | $917.70M |
| 2024-12-31 | $606.10M |
| 2023-12-31 | $566.30M |
| 2022-12-31 | $642.30M |
| 2021-12-31 | $1.05B |
| 2020-12-31 | $817.60M |
| 2019-12-31 | $446.20M |
| 2018-12-31 | $1.14B |
| 2017-12-31 | $548.60M |
| 2016-12-31 | $123.70M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $1.08B | $159.60M |
| 2024-12-31 | $630.70M | $170.40M |
| 2023-12-31 | $511.90M | $150.80M |
| 2022-12-31 | $304.70M | $126.50M |
| 2021-12-31 | $53.30M | $113.40M |
| 2020-12-31 | $276.60M | $119.40M |
| 2019-12-31 | $134.50M | $102.70M |
| 2018-12-31 | $56.10M | $101.90M |
| 2017-12-31 | $26.00M | $106.20M |
| 2016-12-31 | $500.00K | $110.80M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-29
- Consensus EPS estimate
- $0.66
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-30 | Jun/2026 | $0.61 |
| 2026-04-30 | Mar/2026 | $0.47 |
| 2026-02-12 | Dec/2025 | $0.65 |
| 2025-10-30 | Sep/2025 | $0.57 |
| 2025-07-30 | Jun/2025 | $0.45 |
| 2025-05-01 | Mar/2025 | $0.33 |
| 2025-02-13 | Dec/2024 | $0.50 |
| 2025-02-06 | - | - |
Filings and sources
- Company website
- dexcom.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
GE HealthCare Technologies Inc. (GEHC) · Edwards Lifesciences Corp (EW) · STERIS plc (STE) · Boston Scientific Corp (BSX) · Zimmer Biomet Holdings, Inc. (ZBH) · Stryker Corp (SYK) · Globus Medical Inc (GMED) · Medtronic plc (MDT)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades